Client Run Comparison Study Shows Value of Avitar's Oral Fluid Technology
May 04 2006 - 9:30AM
PR Newswire (US)
CANTON, Mass., May 4 /PRNewswire-FirstCall/ -- Avitar, Inc.
(OTC:AVTI.OB) (BULLETIN BOARD: AVTI.OB) -- Avitar, Inc., developer
of the first on-site oral fluid-based screen for drugs of abuse,
today announced the results of a client-conducted month long field
study comparing on-site oral fluid-based drug testing technology to
traditional urinalysis. A client spokesperson, Director of Risk
Management & Human Resources for a mid-sized construction firm,
explained the reasoning for the field test; "While the benefits of
oral fluid-based drug screening were clear to us: instant results,
no risk of sample adulteration, more efficient hiring practices and
a better overall return on our investment in drug testing, we felt
obligated to technically compare the performance of oral fluid
versus urinalysis." The spokesperson continued, "We were impressed
with the results of the study and feel very comfortable that our
drug testing program will more effectively identify those employees
who are using drugs. As a corporation we make every effort to take
advantage of any new technology that contributes to the safety of
our employees and provides better overall value to our customers."
Peter Phildius, CEO and Chairman of Avitar commented, "Our client's
objective comparison between oral fluid-based drug testing and
traditional urinalysis provides yet another example of the
effectiveness of Avitar's technology. Phildius also noted, "The
advantages of oral fluid testing communicated by our client also
enable corporations to efficiently deploy random testing, proven to
be the most effective tool available for eliminating on-the-job
drug abuse." About Avitar Avitar, Inc. develops, manufactures and
markets innovative and proprietary products. Their field includes
the oral fluid diagnostic market, the disease and clinical testing
market, and customized polyurethane applications used in the wound
dressing industry. Avitar manufactures ORALscreen(R), the world's
first non-invasive, rapid, onsite oral fluid test for
drugs-of-abuse, as well as HYDRASORB(R), an absorbent topical
dressing for moderate to heavy exudating wounds. Avitar is also
developing diagnostic strategies for disease and clinical testing
in the estimated $25 billion in-vitro diagnostics market.
Conditions targeted include influenza, diabetes, and pregnancy. For
more information, see Avitar's website at
http://www.avitarinc.com/. Safe Harbor Statement. This release
contains forward looking statements that are subject to risks and
uncertainties including the development and marketing of new
applications and other risks that are detailed from time to time in
the Company's filings with the Securities and Exchange Commission.
In view of such risks and uncertainties, the Company's actual
results could differ materially from those anticipated in such
forward looking statements. Company Contact: PR Contact: Peter
Cholakis Maura Landry Avitar Inc. SHIFT Communications 781-821-2440
x117 617-681-1229 DATASOURCE: Avitar, Inc. CONTACT: Peter Cholakis
of Avitar Inc., +1-781-821-2440 ext. 117, ; or Maura Landry of
SHIFT Communications, +1-617-681-1229, Web site:
http://www.avitarinc.com/
Copyright